A clinical study shows that the level of circulating CD34/prominin-1(CD133)/VEGFR-2-triple positive vascular endothelial progenitor cells are significantly increased in stroke patients receiving NBP treatment compared with controls [18]. The gene discussed is PROM1; the disease is Stroke.